标签归档：rabies

Rabies Virus Glycoprotein TFA

发表于由

Rabies Virus Glycoprotein TFA; 纯度: 99.0%

Rabies Virus Glycoprotein (TFA) 是由 29 个氨基酸残基构成的细胞穿透肽，来源于狂犬病病毒糖蛋白，它能够穿过血脑屏障，进入脑细胞。

Rabies Virus Glycoprotein TFAamp;;

Rabies Virus Glycoprotein TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥1800 In-stock
5 mg ￥4800 In-stock
10 mg ￥8000 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Rabies Virus Glycoprotein TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Rabies Virus Glycoprotein (TFA) is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells[1].

分子量

3380.72

Formula

C143H218N43F3O45S
Sequence

Tyr-Thr-Ile-Trp-Met-Pro-Glu-Asn-Pro-Arg-Pro-Gly-Thr-Pro-Cys-Asp-Ile-Phe-Thr-Asn-Ser-Arg-Gly-Lys-Arg-Ala-Ser-Asn-Gly
Sequence Shortening

YTIWMPENPRPGTPCDIFTNSRGKRASNG
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro:;

H2O : 100 mg/mL (29.58 mM; Need ultrasonic)

DMSO : 100 mg/mL (29.58 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.2958 mL 1.4790 mL 2.9579 mL
5 mM 0.0592 mL 0.2958 mL 0.5916 mL
10 mM 0.0296 mL 0.1479 mL 0.2958 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.74 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.74 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.74 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Zou Z, et al. Cre Fused with RVG Peptide Mediates Targeted Genome Editing in Mouse Brain Cells In Vivo. Int J Mol Sci. 2016 Dec 14;17(12).

Rabies Virus Glycoprotein(Synonyms: 狂犬病病毒糖蛋白)

发表于由

Rabies Virus Glycoprotein;(Synonyms: 狂犬病病毒糖蛋白)

Rabies Virus Glycoprotein 是由 29 个氨基酸残基构成的细胞穿透肽，来源于狂犬病病毒糖蛋白，它能够穿过血脑屏障，进入脑细胞。

Rabies Virus Glycoproteinamp;;(Synonyms: 狂犬病病毒糖蛋白)

Rabies Virus Glycoprotein Chemical Structure

规格 价格 是否有货
1 mg ￥1800 询问价格 货期
5 mg ￥5400 询问价格 货期

* Please select Quantity before adding items.

Rabies Virus Glycoprotein 的其他形式现货产品:

Rabies Virus Glycoprotein TFA

生物活性

Rabies Virus Glycoprotein is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells.

体外研究
(In Vitro)

RVG peptide is successfully used to carry a variety of cargos into brain cells such as plasmids, siRNAs, proteins, and nanoparticles[1]. RVG29 can govern the interaction of viral particles with at least three known receptors, including neural cell adhesion molecule (NCAM), the p75 neurotrophin receptor (P75NTR), and nicotinic acetylcholine receptors (NAChRs). The RVG29 peptide enhances the brain-specific function of a range of systemically delivered agents, particularly nucleic acids[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

3266.70

Formula

C141H217N43O43S2
Sequence

Tyr-Thr-Ile-Trp-Met-Pro-Glu-Asn-Pro-Arg-Pro-Gly-Thr-Pro-Cys-Asp-Ile-Phe-Thr-Asn-Ser-Arg-Gly-Lys-Arg-Ala-Ser-Asn-Gly
Sequence Shortening

YTIWMPENPRPGTPCDIFTNSRGKRASNG
中文名称

狂犬病病毒糖蛋白
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Zou Z, et al. Cre Fused with RVG Peptide Mediates Targeted Genome Editing in Mouse Brain Cells In Vivo. Int J Mol Sci. 2016 Dec 14;17(12). pii: E2104.

    [2]. Cook RL, et al. A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system. J Control Release. 2015 Dec 28;220(Pt A):89-97.